My ePortfolio Register   

Multiple myeloma analysis from ASH 2017

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
This content is restricted to members who are registered with ecancer as a healthcare professional.
Please login or register for free to confirm your details.
Published: 12.12.17
Views: 1310

Dr Maxim Solovev and Dr Sung-Soo Yoon

During this expert discussion, Dr Maxim Solovev from National Research Centre for Haematology, Moscow, Russia and Dr Sung-Soo Yoon from Seoul National University, Seoul, South Korea and looked at the impact recent data releases, from the 59th annual American Society of Haematology conference in Atlanta, would have on patients living with multiple myeloma.

During this session, the two clinicians discussed abstracts that covered treatment strategies for newly diagnosed multiple myeloma (NDMM) and relapsed or refractory multiple myeloma (RRMM), including daratumumab plus lenalidomide and dexamethasone (DRd), lenalidomide plus dexamethasone (Rd), and from the APRIL study and results from trials including ixazomib as a treatment option.

This programme has been supported by an unrestricted educational grant from Takeda

Related videos

follow us

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence